Cancer News and Research

Latest Cancer News and Research

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology

Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology

Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma

Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

Protein alpha-2-beta-1 integrin suppresses metastasis

Protein alpha-2-beta-1 integrin suppresses metastasis

PET/CT scan predicts, detects local recurrence after radiofrequency ablation

PET/CT scan predicts, detects local recurrence after radiofrequency ablation

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Smoking is common among young adults and children with diabetes, raises risk of heart disease

Smoking is common among young adults and children with diabetes, raises risk of heart disease

New ways to identify patients most likely to respond to cancer vaccine treatment

New ways to identify patients most likely to respond to cancer vaccine treatment

Medication and blood transfusion reduce risk of recurrent strokes in young patients with sickle cell anemia

Medication and blood transfusion reduce risk of recurrent strokes in young patients with sickle cell anemia

Reason behind recurrence of CLL in lymph nodes and bone marrow after chemotherapy

Reason behind recurrence of CLL in lymph nodes and bone marrow after chemotherapy

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Low dose of aspirin reduces occurrence of several common cancers: Study

Low dose of aspirin reduces occurrence of several common cancers: Study

New analysis shows that common diseases are not lined to genetic factors

New analysis shows that common diseases are not lined to genetic factors

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.